Beta Bionics, Inc. (NASDAQ:BBNX - Get Free Report) shares traded up 7.2% on Thursday . The stock traded as high as $15.52 and last traded at $15.47. 133,660 shares changed hands during trading, a decline of 72% from the average session volume of 477,213 shares. The stock had previously closed at $14.43.
Analyst Ratings Changes
Several research firms recently issued reports on BBNX. Wolfe Research assumed coverage on Beta Bionics in a research report on Friday. They issued an "outperform" rating and a $20.00 price objective on the stock. Baird R W upgraded Beta Bionics to a "hold" rating in a research note on Thursday, February 20th. Lake Street Capital assumed coverage on Beta Bionics in a report on Monday, February 24th. They set a "buy" rating and a $30.00 price target on the stock. The Goldman Sachs Group began coverage on Beta Bionics in a report on Friday. They issued a "neutral" rating and a $16.00 price objective for the company. Finally, Piper Sandler began coverage on Beta Bionics in a research report on Monday, February 24th. They issued an "overweight" rating and a $26.00 target price for the company. Four analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $23.13.
View Our Latest Analysis on Beta Bionics
Beta Bionics Price Performance
The business has a 50 day moving average of $12.38.
Beta Bionics (NASDAQ:BBNX - Get Free Report) last released its earnings results on Tuesday, May 6th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.01).
Institutional Investors Weigh In On Beta Bionics
A number of institutional investors and hedge funds have recently bought and sold shares of the company. Driehaus Capital Management LLC purchased a new position in shares of Beta Bionics during the first quarter valued at $10,799,000. Ghisallo Capital Management LLC purchased a new position in Beta Bionics during the 1st quarter valued at about $612,000. Omega Fund Management LLC bought a new stake in shares of Beta Bionics in the 1st quarter valued at about $24,337,000. Walleye Capital LLC purchased a new stake in shares of Beta Bionics in the 1st quarter worth approximately $1,813,000. Finally, Wellington Management Group LLP purchased a new stake in shares of Beta Bionics in the 1st quarter worth approximately $47,346,000.
About Beta Bionics
(
Get Free Report)
Beta Bionics, Inc is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.
See Also
Before you consider Beta Bionics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Beta Bionics wasn't on the list.
While Beta Bionics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
